Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2018 August;70(4) > Minerva Ginecologica 2018 August;70(4):402-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  FERTILITY PRESERVATION IN WOMEN 

Minerva Ginecologica 2018 August;70(4):402-7

DOI: 10.23736/S0026-4784.18.04232-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Indications for fertility preservation in women from malignant diseases to benign conditions to age-related fertility decline

Marie-Madeleine DOLMANS 1, 2 , Jacques DONNEZ 3, 4

1 Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium; 2 Department of Gynecology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; 3 Catholic University of Louvain, Brussels, Belgium; 4 Société de Recherche pour l’Infertilité (SRI), Brussels, Belgium


PDF


Oocyte vitrification and ovarian tissue cryopreservation are two common fertility preservation options. Oocyte vitrification provides the highest yield for women with benign diseases or those seeking fertility preservation for age-related fertility decline. This technique is also indicated for cancer women if cancer treatment can be postponed. Ovarian tissue cryopreservation has some specific indications. There is indeed no other alternative for fertility preservation in prepubertal girls, and in cancer women in whom cancer treatment cannot be postponed. This review focuses on the indications for fertility preservation from malignant diseases to benign conditions to age-related fertility decline.


KEY WORDS: Fertility preservation - Cryopreservation - Oocytes - Vitrification

top of page